Stanley Druckenmiller Invests in Revolution Medicines Amid Strong Clinical Results
Billionaire investor Stanley Druckenmiller's Duquesne Family Office has taken a $30.7 million position in Revolution Medicines (NASDAQ: RVMD) as of the first quarter of 2026, following the biotech company’s significant stock surge exceeding 400% over the past year. The investment is attributed to promising late-stage clinical results for daraxonrasib, a drug targeting pancreatic cancer by inhibiting RAS proteins considered difficult to treat in oncology. Daraxonrasib demonstrated median overall survival of 13.2 months compared to chemotherapy's typical rate, leading Revolution Medicines to seek FDA and European regulatory approvals. The company is valued at approximately $40 billion with high expectations for future revenue potential from daraxonrasib alone ranging between $5 billion and $7.6 billion annually.
Tickers: $RVMD
Topics: biotech cancer therapy FDA approval stock performance